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SUMMARY 
The c-ABL non-receptor tyrosine kinase is a pivotal upstream positive modulator in 
cellular response to DNA damage, which attributes to the activation of p53 family 
proteins, hence the expression of p53 target proteins promoting DNA repair, growth 
arrest or apoptosis. However, a comprehensive understanding of the role of c-ABL 
kinase in p53-dependent transcription of p21CIP1/WAF1 and ensuing cell fate decision is 
still obscure.   
Here, I demonstrate that c-ABL tyrosine kinase regulates p53-dependent 
induction of p21. As a result, it modulates cell fate decision by p53 in response to DNA 
damage differently according to the extent of DNA damage.  When human cancer cells 
were treated with DNA damaging agent, adriamycin (0.08 µg/ml), p21 was induced 
following p53 induction. Owing largely to p21, a substantial fraction of cells treated with 
adriamycin were blocked at the G2 phase of the cell cycle and most cells eventually 
became senescent. When these cells were simultaneously treated with a c-ABL kinase 
inhibitor, STI571, or a c-ABL-specific siRNA along with adriamycin, the p53-dependent 
p21 induction was dramatically diminished, even though p53 is substantially induced. 
Accordingly, G2-arrest, and cellular senescence largely dependent on p21 was 
substantially abrogated.  On the contrary, when cells were treated with a relatively high 
dose of adriamycin (0.4 µg/ml) cells became apoptotic, and the simultaneous presence 
of a c-ABL kinase inhibitor STI571 augmented the extent of apoptosis. I speculate this is 
due to abrogation of p53-dependent p21 induction, which leads to elimination of anti-
apoptotic function of p21.  
11 
 
In conclusion, c-ABL appears to promote senescence or inhibit apoptosis, 
depending on the extent of DNA damage. These findings suggest that the combined 
use of ABL kinase inhibitor and DNA damaging drug in chemotherapy against tumors 
retaining wild type p53 should be carefully designed. 
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1. GENERAL INTRODUCTION 
The following literature review provides background information for the results section 
(Chapter 4). It will start with an overview of c-ABL non-receptor tyrosine kinase, which is 
a central element of this research project. Then, the role of c-ABL in DNA damage 
response explored at cellular level will be overviewed. Finally, the cellular senescence, 
which is expected to be induced by c-ABL after DNA damage will be reviewed. 
 
1.1 The c-ABL tyrosine kinase 
Tyrosine kinase is an enzyme that catalyzes the transfer of phosphate groups from ATP 
to tyrosine residues of polypeptides (Krause and Van Etten, 2005). Tyrosine kinases are 
broadly classified as receptor tyrosine kinases and non-receptor tyrosine kinases. The 
c-ABL is a non-receptor tyrosine kinase and is closely related to the Src family of non-
receptor tyrosine kinase sharing kinase domain with extensive homology. ABL-related 
gene (Arg) or ABL2 is the only known paralogue of ABL1 (c-ABL) (Hantschel and 
Superti-Furga, 2004). The c-ABL is implicated in a wide range of cellular processes, 
including meiosis, embryonic and neonatal development, during which its tyrosine 
kinase activity is strictly regulated (Kharbanda et al., 1998a; Tybulewicz et al., 1991; 
Wang, 2000). However, pathological or physiological activation of c-ABL occurs under 
various conditions. In chronic myelogenous leukemia, chromosomal rearrangement 
transforms c-ABL into an oncogenic BCR-ABL chimeric protein with enhanced kinase 
activity (Collins et al., 1987; Lugo et al., 1990). Aberrant activation of c-ABL kinase 
activity is also involved in other disorders, such as neurodegenerative diseases, genesis 
of solid tumours, or aging of organisms (Schlatterer et al., 2011; Sirvent et al., 2008; 
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Soleimani et al., 2011; Yuan et al., 2010). In addition, c-ABL kinase activity is up-
regulated during DNA damage responses (Liu et al., 1996; Maiani et al., 2011). The 
following subsections will briefly collate structural and functional studies done on c-ABL, 
and also its involvement in a wide range of cellular processes.  
 
1.1.1 The c-ABL gene, isoforms and structure 
Abelson murine leukemia viral oncogene homolog 1 also known as c-ABL is encoded 
by the ABL1 gene located on chromosome 9 in human. The evolutionarily conserved 
mammalian c-ABL was originally identified as the cellular homolog of the transforming 
v-Abl oncogene of the Abelson murine leukemia virus (Abelson and Rabstein, 1970; 
Goff et al., 1980). The c-ABL is a 145 KDa protein that is highly conserved and 
expressed ubiquitously in the cells and localizes both to the nucleus and the cytoplasm 
where it plays distinct roles (Goga et al., 1995; Kharbanda et al., 1998b; Shaul and Ben-
Yehoyada, 2005; Wang, 2000). The cytoplasmic c-ABL regulates cell proliferation 
response, whereas the nuclear c-ABL can be growth arresting and/or pro-apoptotic 
(Goga et al., 1995; Kharbanda et al., 1998b; Wang, 2000). In response to DNA damage, 
c-ABL translocates to the nucleus, thereby shutting down cytoplasmic function of 
promotion of proliferation and eliciting nuclear function of DNA damage response 
pathway. In humans, the ABL1 gene gives rise to two different forms of c-ABL, 1a and 
1b, as a result of alternative splicing from separate promoters found on the ABL1 gene 
(Figure 1.1).  Although, both isoforms are present in the nucleus and cytoplasm; the 1a 
isoform is mostly cytoplasmic, while the 1b isoform localizes predominantly to the 
nucleus (Shaul and Ben-Yehoyada, 2005). 
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(Hantschel, O., and Superti-Furga, G.; 2004) 
Figure 1.1 Domain structure of the c-ABL tyrosine kinase. 
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(Hantschel, O., and Superti-Furga, G.; 2004) 
Figure 1.2 Structure of regulated c-ABL in complex with the kinase inhibitor PD166326. 
 
The ABL kinase constitutes of two parts: an N-terminal half and a C-terminal half. 
In the N-terminal half, ABL kinase contains an N terminal cap, Src Homology 2 (SH2) 
and Src Homology 3 (SH3) domains, which are about 80, 100 and 50 residues long, 
respectively. N-terminus at the cap region is important for lipid modification of c-ABL as 
it contains the consensus sequence for myristoylation, which is not present in type 1a 
(Figure 1.1). The C14 myristoyl fatty acid at the amino terminus is essential for 
regulating c-ABL activation and is the main difference between the gene variants 
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(Hantschel and Superti-Furga, 2004; Nagar et al., 2003). The SH2 domain has an SH2 
fold as a beta sheet packed between 2 alpha helices. The SH3 domain forms a "beta-
barrel fold," in which several beta strands are assembled into 2 compact sheets (Figure 
1.2).  After SH2-kinase linker there is a tyrosine kinase domain, which encloses the 
ATP-binding site. The ATP binding site holds two important regions: the activation loop 
and the phosphate-binding loop (P-loop).  On the other hand, the C-terminal half 
contains binding elements for the SH3 domain, three nuclear localization signals (NLS), 
a nuclear export signal (NES), a DNA binding domain, and an actin-binding domain 
(Nagar, 2007; Taagepera et al., 1998; Van Etten et al., 1989). NLS and NES domains 
enabling c- ABL to shuttle between the cytoplasm and nucleus allows c-ABL to exert its 
specific roles pre-determined by its sub-cellular localization (Van Etten, 1999).  
The c-ABL can form fusion proteins with other genes such as v-Abl (viral-Abl), 
BCR-ABL (Breakpoint cluster-ABL), etc. These fusion genes create oncogenes having 
transformation ability (Van Etten et al., 1989). Fusion between Gag viral protein (M-
MulV) and the SH2 domain of c-ABL give rises to v-Abl that can be myristoylated 
making its exclusive localization to the cytoplasm. It possesses potent tyrosine kinase 
activity and can induce pre-B cell leukemia in mice. On the other hand, fusion of the N-
terminal sequences of BCR to almost full-length c-ABL produces the BCR-ABL 
oncoprotein, which is constitutively active and is localized in the cytoplasm. Although 
DNA damage can induce its nuclear translocation, under unstressed condition it is 
exclusively localized in the cytoplasm (Dierov et al., 2004). In human, Chronic 
myelogenous leukemia (CML) and a subset of acute lymphoblastic leukemia (ALL) are 
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causally associated to the expression of BCR-ABL (Advani and Pendergast, 2002; 
Goldman and Melo, 2003). 
 
1.1.2 The c-ABL biology using mouse genetics  
The physiological functions of c-Abl have been exploited mainly by the use of c-Abl 
knockout mice. The c-Abl is expressed ubiquitously throughout mouse embryonic 
development. Genetic studies of c-Abl-/- mice have demonstrated its essential role in 
development. Mice having the null allele for c-Abl are mostly perinatally lethal, and 
those that survive the first 3 days (<50%) exhibit several developmental abnormalities 
coupled with complex phenotypes such as shortened-lifespan, infertility, runtedness, 
thymus and spleen atrophies and osteoporosis (Schwartzberg et al., 1991; Tybulewicz 
et al., 1991) Through genetic analysis using c-Abl knockout mice having c-Abl deletion 
or truncation it was found that the carboxy-terminal region was critical for c-Abl function 
in vivo (Li et al., 2000). 
 
1.1.3 Regulation of c-ABL tyrosine kinase activity 
The tyrosine kinase activity of c-ABL is very tightly controlled in the cell. This is 
achieved by autoinhibition that relies on a complex set of intra-molecular interactions of 
the SH3 and SH2 domains and all other segments in the amino-terminal half of the 
protein including the myristoyl group; the SH3–SH2 connector; the SH2–kinase-domain 
linker (Figure 1.2). Through intra-molecular interactions the SH3 and the SH2 domains 
are bound to the distal side of the kinase domain and oppose the active site. Binding of 
phosphopeptides to the SH2 domain of auto-inhibited c-ABL will lead to kinase 
activation by disrupting the SH2–kinase-domain interface. Moreover, cellular substrates 
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of c-ABL such as c-JUN, ABL interactor 1 (Abi1), p21-activated kinase γ (γ-PAK), 
CDK5, ABL enzyme substrate 1 (Cables), etc can initially be phosphorylated by basal 
kinase activity of c-ABL or other kinases, thereby initiating a positive feed-forward 
regulation involving SH2- domain-dependent activation of c-ABL kinase activity 
(Hantschel and Superti-Furga, 2004).  
The auto-inhibitory form of c-ABL is not phosphorylated on tyrosine residues of 
Y412, Y245, whereas higher levels of phosphotyrosine are detected when auto-
inhibitory constraints are disrupted by mutations. These phosphorylations stabilize the 
active conformation of the ABL kinase domain and are necessary for kinase activation. 
When unphosphorylated, the activation loop of the ABL kinase domain folds into the 
active site, thereby preventing binding of both the substrate and ATP. Furthermore, 
Y134 is a conserved residue of SH3 domains that is directly involved in binding to PXXP 
ligands. When the Y134 is phosphorylated proper binding of the linker to the SH3 
domain does not occur, and thereby interfere with auto-inhibition. On the other hand, Rb 
(the tumor suppressor retinoblastoma protein) is known to inhibit c-ABL kinase activity 
by interacting with the ATP-binding lobe of the ABL kinase but not to the SH3 domain 
(Hantschel and Superti-Furga, 2004). 
 
1.1.4 Pharmacologic inhibition of ABL kinase 
STI-571, also known as Gleevec or imatinib mesylate, is a 2-phenylaminopyrimidine 
derivative (Figure 1.3A) that specifically inhibit ABL kinase and is the first successful 
drug for treating BCR-ABL positive leukaemias, including most cases of CML and a 
subset of ALL (Druker et al., 2001; Druker et al., 1996). 
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The crystal structure of the ABL kinase domain in complex with STI-571 (Figure 
1.3B) shows that it binds to the conserved ATP-binding pocket and forces the activation 
loop into an inactive, non-phosphorylated conformation (Hantschel and Superti-Furga, 
2004; Nagar et al., 2002).  Since STI571 represses BCR-ABL functions as well as that 
of c-ABL, a combination therapy e.g., STI571 with MDM2 inhibitor nutlin or genotoxic 
drug such as cisplatin, adriamycin can boost apoptotic response in patients bearing wild 
type p53 (Fruehauf et al., 2007; Goldberg et al., 2004; Skorta et al., 2009).  
 
(Hantschel, O., and Superti-Furga, G.; 2004) 
Figure 1.3 (A) Chemical formula of STI571. (B) Crystal structure of the ABL kinase domain in 
complex with STI-571.  
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1.2 Activation of c-ABL in the response to DNA damage 
DNA damage inducers such as ionizing radiation (IR), cisplatin, etoposide, adriamycin, 
camptothecin are known to activate c-ABL tyrosine kinase (Gonfloni et al., 2009; Gong 
et al., 1999; Kharbanda et al., 1995; Wang, 2000). These DNA damaging agents 
activate c-ABL kinase by stimulating ATM. Binding of ATM to the SH3 domain of c-ABL 
results in a significant increase of c-ABL kinase activity. Furthermore, phosphorylation 
of c-ABL by ATM on Ser-465 results in the activation of c-ABL kinase (Baskaran et al., 
1997). On the contrary, the activated c-ABL has been demonstrated to phosphorylate 
ATM/ATR and this phosphorylation is required for proper activation of both ATM and 
ATR (Wang et al., 2011). Thereby it appears that there is a positive feedback regulation 
between ATM and c-ABL (Figure 1.4). The c-ABL is known to play a crucial role in the 
cellular responses to DNA damage, which include cell cycle arrest, DNA repair and 
apoptosis.  
  
Figure 1.4 Positive feedback regulation between c-ABL and ATM 
 
1.2.1 Role of c-ABL in activation of p53 family proteins 
In response to DNA damage c-ABL is known to phosphorylate p73 on specific tyrosine 
residues (Gong et al.1999; Agami et al., 1999; Kharbanda et al., 1998). All of the target 
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tyrosine residues of p73 are also conserved in p63, which correspond to residues 
Tyr149, Tyr171 and Tyr289 (Gonfloni et al., 2009). Phosphorylation of these residues 
on p63 (and p73) by c-ABL causes stabilization and activation of p63 and p73 that result 
in apoptosis (Agami et al., 1999; Costanzo et al., 2002; Gonfloni et al., 2009; Gong et 
al., 1999; White and Prives, 1999), (Figure 1.5). However, the role of c-ABL in p53 
activation is rather indirect and still largely elusive. The p53 lacks canonical c-ABL 
phosphorylation sites. The c-ABL tyrosine kinase has been shown to phosphorylates  
 
Figure 1.5 Activation of p53 family proteins by c-ABL 
 
ATM/ATR in a kinase dependent manner and this activated ATM/ATR in turn 
phosphorylates p53 and increases its transactivation activity in response to DNA 
damage (Wang et al. 2011) (Figure 1.5). Furthermore, both the activated ATM and c-
ABL kinase has been demonstrated to phosphorylate and inactivate MDM2 and MDMX 
neutralizing their inhibitory effects on p53 (Khosravi et al., 1999; Zuckerman et al., 
2009). Consequently, the activated p53 increases the transcription of p21, GADD45 and 
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14-3-3σ and induces cell cycle arrest (Wang et al., 2011). On the other hand, Jing et. 
al., 2007, have reported that tyrosine kinase activity of c-ABL is not required for p53 
dependent transactivation of p21. They have demonstrated that c-ABL interacts with c-
terminal region of p53 and this interaction increases the binding affinity of p53 towards 
p21 promoter leading to induction of p21 transcription (Jing et al., 2007; Nie et al., 
2000). 
 
1.2.2 Role of c-ABL in DNA-damage-induced cell cycle arrest 
The cell cycle checkpoint control mechanisms can generate a transient delay, referred 
to as cell cycle arrest, and allows DNA repair to occur before progressing to the next 
phase of the cycle. The tumor suppressor p53 is a checkpoint protein that can halt the 
cell cycle upon DNA damage induced by genotoxic insults. In this signaling pathway c-
ABL and ATM act upstream of p53. A potent CDK inhibitor p21, a transcriptional target 
of p53, is another important protein in this signaling cascade. The p21 binds to a 
number of cyclin and CDK complexes, and inhibits the CDK kinase activity, resulting in 
blockade of cell cycle progression. The c-ABL turned out to be a central molecule in this 
signaling cascade and it is involved in the regulation of cell cycle arrest at both G1 and 
G2 check points. Cells expressing the dominant-negative c-ABL kinase mutant and the 
c-ABL nullizygous fibroblasts are impaired in their ability to downregulate CDK2 or 
undergo G1 arrest in response to ionizing radiation (Yuan et al., 1996a; Yuan et al., 
1996b). On the other hand, inhibition of c-ABL kinase activity by STI571 or stable c-ABL 
knockdown abolishes mismatch repair (MMR)-dependent G2 arrest in MMR-proficient 
cells exposed to N-methyl-N′-nitro-N′-nitrosoguanidine (Wagner et al., 2008). 
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 1.2.3 Role of c-ABL in DNA repair 
Rad51 functions in homologous recombination repair pathway of double strand DNA 
break (Baumann et al., 1996). In response to DNA damage the c-ABL phosphorylates 
and regulates Rad51 to control recombination (Yuan et al., 1998). The interaction 
between c-ABL and Rad51 might occur with accumulation of DNA double-strand breaks 
during meiotic recombination or class switching. In addition, c-ABL is expressed at high 
levels in pachytene spermatocytes, thereby it seems that c-ABL plays a crucial 
functional role in meiosis (Kharbanda et al., 1998a).  
 
1.2.4 Role of c-ABL in the regulation of apoptosis 
A number of reports have shown that the c-ABL tyrosine kinase induces apoptosis. The 
cells expressing dominant negative c-ABL (Kinase dead) mutant exhibit resistance to 
apoptosis induction by IR and other DNA damaging agents (Huang et al., 1997; Yuan et 
al., 1997). This proapoptotic function of c-ABL is shown to be largely mediated by p63 
and p73 tumor suppressor proteins. c-ABL can phosphorylates p63/p73 in vitro and in 
cells exposed to certain DNA damaging agents leading to stabilization of p63/p73 
proteins (Agami et al., 1999; Gonfloni et al., 2009; Gong et al., 1999; White and Prives, 
1999). In contrast, p53 lacks target phosphorylation site by c-ABL.  Nevertheless, the 
interaction between c-ABL and p53 has been shown to contribute to DNA damage-
induced cell cycle arrest response rather than apoptosis (Yuan et al., 1996a; Yuan et 
al., 1996b). In contrast to the evidence in support of a pro- apoptotic role of c-ABL, other 
studies have shown that c-ABL has an anti-apoptotic effect (Dorsch and Goff, 1996). 
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Indeed, expression of constitutively active BCR-ABL fusion protein confers resistance to 
induction of apoptosis by genotoxic drugs (Bedi et al., 1995). 
 
1.3 Cellular senescence 
Following a limited number of cell divisions normal somatic cells cease to proliferate and 
enter a state called replicative senescence, because of telomere attrition. Cellular 
senescence can also be induced by DNA damage, oxidative stress, or oncogenic 
activation in a telomere-independent manner. This type of cellular senescence is usually 
referred to as stress-induced premature senescence (Ben-Porath and Weinberg, 2005). 
Cells entering senescence undergo permanent growth arrest exhibiting characteristic 
features including enlarged and flattened shape, increased granularity, and expression 
of senescence-associated β-galactosidase (SA-β-gal) (Dimri et al., 1995). Since 
senescent cells never re-enter the cell cycle, the cellular senescence can prevent 
malignant transformation and thus functions as a potent tumor suppressor (Chen et al., 
2005). However, senescent cells can not be eliminated by cell death remaining within 
tissues and acquire modified functions to change tissue microenvironments in ways that 
can promote cancer and/or organismal aging (Rodier et al., 2007). 
 
1.3.1 Signaling pathways of senescence 
Regardless of diverse stimuli in inducing senescent state, the p53/p21 and Rb/p16 axes 
are the two most dominant tumor suppression pathways implicated in cellular 
senescence (Ben-Porath and Weinberg, 2005).  p53 deficiency results in an escape 
from senescence and spontaneous immortalization in mouse cells, while p16INK4a 
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deficiency delays the onset of senescence. In some cell types, both p53 and p16INK4a 
are required for the onset of senescence  (Kuilman et al., 2010). On the other hand, p53 
and p21 are known to act as positive regulators of senescence in drug-treated tumor 
cells. For instance, the adriamycin-induced senescence is regulated to a large extent by 
p21. In particular, inhibition of p53-dependent p21induction diminishes adriamycin-
induced senescence and overexpression of p21 induces the senescent phenotype 
(Chang et al., 1999).  
 
1.3.2 Role of c-ABL in cellular senescence 
In response to DNA damage c-ABL in known to induce growth arrest p53 dependent 
manner (Wagner et al., 2008; Wang et al., 2011; Yuan et al., 1996a; Yuan et al., 
1996b). c-ABL has been shown to interact with p53 and enhance p21 expression (Jing 
et al., 2007; Yuan et al., 1996a). Thereby, I speculated that c-ABL might have a 
profound role in DNA damage-induced senescence.  Although, the functions of c-ABL in 
cell cycle arrest or apoptosis has been studied extensively, its effect on cellular 
senescence following DNA damage remains to be elucidated. 
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 2. RATIONALE AND AIM OF THE THESIS 
2.1 Thesis rationale 
c-ABL is a proto-oncoprotein belonging to the Src family of non-receptor tyrosine 
kinases that is ubiquitously expressed in cells and tissues (Shaul and Ben-Yehoyada, 
2005). c-ABL is implicated in a wide range of cellular processes, including meiosis, and 
embryonic and neonatal development (Kharbanda et al., 1998a; Tybulewicz et al., 1991; 
Wang, 2000), during which its tyrosine kinase activity is strictly regulated. However, 
pathological or physiological activation of c-ABL occurs under various conditions. In 
chronic myelogenous leukemia, chromosomal rearrangement transforms c-ABL into an 
oncogenic BCR-ABL chimeric protein with enhanced kinase activity (Collins et al., 1987; 
Lugo et al., 1990). Aberrant activation of c-ABL kinase activity is also involved in other 
disorders, such as neurodegenerative diseases, genesis of solid tumours, or aging of 
organisms (Schlatterer et al., 2011; Sirvent et al., 2008; Soleimani et al., 2011; Yuan et 
al., 2010). In addition, c-ABL kinase activity is up-regulated during DNA damage 
responses (Liu et al., 1996; Maiani et al., 2011). Members of the p53 family of proteins 
are also induced during DNA damage response. During this process, activated c-ABL 
kinase phosphorylates and stabilizes p63/p73, thereby contributing to the induction of 
cell apoptosis (Agami et al., 1999; Gonfloni et al., 2009; Gong et al., 1999; White and 
Prives, 1999). Although p53 is also phosphorylated and acetylated upon DNA damage 
(Prives and Hall, 1999; Sakaguchi et al., 1998), the role of c-ABL in the activation of p53 
is rather elusive, since p53 lacks canonical c-ABL phosphorylation sites. It is considered 
that c-ABL kinase-mediated activation of p53 during DNA damage response occurs 
indirectly via multiple ways (Wang et al., 2011; Zuckerman et al., 2009).  
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At the cellular level, the extent of DNA damage determines whether cells are 
destined to undergo cell cycle arrest, cellular senescence, or apoptosis (Erol, 2011; 
Zhang et al., 2009), and p53 plays a central role in governing the cell fate. At relatively 
high levels of DNA damage, p53 is induced and triggers apoptosis (Kracikova et al., 
2013); this process requires p63/p73, which are also induced by severe DNA damage 
(Flores et al., 2002; Kurihara et al., 2007). On the other hand, at relatively low levels of 
DNA damage, induction of p21CIP1/WAF1 (hereafter referred to p21), in addition to p53, 
evokes cell cycle arrest and promotes cell survival and senescence (Chang et al., 1999; 
Han et al., 2002; McKenna et al., 2012). Cellular senescence caused by a low dose of 
the DNA damaging agent adriamycin (ADR) is remarkably abrogated upon knock-down 
of either p53 or p21 (Chang et al., 1999). In addition, p21 can have an antagonistic 
effect on apoptosis (Gartel and Tyner, 2002; Han et al., 2002; Janicke et al., 2007). By 
activating the p53/p21 signalling pathway, c-ABL kinase is also involved in the control of 
cell fate following DNA damage (Kharbanda et al., 1998b; Wagner et al., 2008; Wang et 
al., 2011; Yuan et al., 1996a; Yuan et al., 1996b). When the DNA damage is irreparable, 
cells may progress to cellular senescence or apoptosis.  
Despite the findings described above, it is still unclear the functions of c-ABL, 
p53, and p21 as an integrity can be involved in the control of apoptosis, cell cycle arrest, 
and senescence depending on the extent of DNA damage. Thus, in this study, I 
analyzed the role of c-ABL kinase in p53-dependent induction of p21 in detail. By doing 
so, I have found that this regulation of p53-dependent induction of p21 by c-ABL have 
profound effects on p53-dependent cell fate determination in response to DNA damage. 
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Furthermore, the findings also have significant insight into the combined use of 
chemotherapeutic drugs and ABL kinase inhibitors in the treatment of cancers. 
 
My project employs human cancer cell lines and I used a genotoxic drug adriamycin to 
induce DNA damage response. The results provide a better insight into the 
understanding of physiological functions of c-ABL in cellular senescence.  
This thesis is divided into 5 chapters; 
Chapter 1 contains general literature review to provide background information for this 
project. 
Chapter 2 contains rational and aim of the thesis. 
Chapter 3 describes the materials and methods used for this study. 
Chapter 4 demonstrates the function of c-ABL tyrosine kinase in the determination of 
the cell fate decision by p53-dependent p21 induction following DNA damage.  
Chapter 5 is general discussion and future perspectives. 
Chapter 6 is conclusion. 
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2.2 Aims of the thesis 
The aim of this thesis is to elucidate the comprehensive understanding of the role of c-
ABL kinase in p53-dependent transcription of p21CIP1/WAF1 and ensuing cell fate decision 
following DNA damage responses, with particular focus on the following topics: 
1. The kinase activity of c-ABL is prerequisite for p53-dependent p21 induction in 
response to DNA damage. 
2. The c-ABL tyrosine kinase affects cell fate decision destined to cell cycle arrest, 
senescence or apoptosis by activating p53/p21 pathway according to the extent 
of DNA damage. 
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3. MATERIALS AND METHODS 
3.1 Cell culture, chemicals, plasmids, and antibodies 
A human osteosarcoma cell line U2OS, a human cervical carcinoma cell line HeLa, and 
a human lung adenocarcinoma cell line A549 were cultured in Dulbecco’s Modified 
Eagle’s medium (DMEM) (Wako, Japan) supplemented with 10% fetal bovine serum in 
a 5% CO2 incubator at 37°C. Cells were treated with ADR (Sigma-Aldrich, MO, USA) 
and STI571 (LKT Laboratories Inc., MN, USA). The c-Abl wild-type (WT) expression 
plasmid was a kind gift from Dr. Jean Y. J. Wang (University of California, San Diego). 
The following antibodies were used according to the manufacturers’ recommendations.  
 
 
Table 2.1 List of antibodies used 
Antibody Type/ Host Clone, and  Catalogue number Brand/company Dilution 
p21WAF1/CIP1 Monoclonal/mouse AB-6, # OP79 Calbiochem, San Diego, CA, USA 1:200 
p53 Polyclonal/ rabbit FL-393, # sc-6243 Santa Cruz, Santa Cruz, CA, USA 1:1000 
p-p53 ser15 Polyclonal/ rabbit # 9284 
Cell Signaling 
Technology, Beverly, 
MA, USA 
1:1000 
c-Abl Monoclonal/mouse 8E9, # 554148 BD Pharmingen, Tokyo, Japan 1:1000 
α-tubulin Monoclonal/mouse DM1A, # T9026  Sigma-Aldrich, St. Louis, MO, USA 1:2000 
β-actin Monoclonal/mouse AC15, # A5441 Sigma-Aldrich, St. Louis, MO, USA 
1:2000 
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3.2 Cell transfections  
Cells were seeded onto 10 cm dishes at a density of 1.5 × 106 cells per dish. After an 
overnight incubation, the cells were transiently transfected with plasmid DNA using 
Lipofectamine 2000 reagent (Invitrogen, Tokyo, Japan). The siRNA transfections were 
performed using 50 nM of siRNA and Lipofectamine RNAiMax reagent (Invitrogen). 
ABL1-specific (SASI_Hs01_00174552, SASI_Hs01_00174553, and 
SASI_Hs01_00174554) and control (MISSION siRNA universal negative control #1, 
SIC-001) siRNAs were purchased from Sigma-Aldrich. 
 
3.3 Luciferase assay  
Cells were transfected with 1 μg of MSCV empty vector or c-ABL WT expression 
plasmid using the CaPO4 method (Mammalian Transfection Kit, Statagene, CA, USA). 
These cells were co-transfected with 100 ng of the p21-Luc vector and 10 ng of the 
pRL-CMV vector. In brief, cells were seeded into 24-well plates at a density of 1 × 105 
cells per well and then incubated overnight prior to transfection. The desired amount of 
expression plasmid was diluted with distilled, deionized water to a final volume of 45 μl. 
Five microliters of solution 1 (2.5 M CaCl2) and 50 μl of solution 2 (2 × BBS (pH 6.95), 
consisting of 50 mM N, N-bis (2-hydroxyethyl)-2-aminoethanesulfonic acid and buffered 
saline, 280 mM NaCl, and 1.5 mM Na2HPO4) were added to the diluted plasmid DNA 
and the solution was incubated at room temperature for 10–20 min. The resulting 100 μl 
DNA suspension was added to each well and then the cells were incubated for 18 h in 
serum-free medium in 3% CO2-atmosphere at 37°C. The cells were incubated for a 
further 6 h in fresh complete medium, and then treated with ADR or STI571 for 48 h. 
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Cell lysates were prepared and the relative luciferase activity was analysed using a 
Luminescencer-JNR AB-2100 luminometer (ATTO, Tokyo, Japan) and the dual-
luciferase assay system (Promega, Madison, WI, USA). Firefly luciferase activity was 
normalized to Renilla luciferase activity. The statistical significance was determined by a 
paired Student’s t-test; P < 0.05 was considered significant. 
 
3.4 Protein extraction and immunoblot analyses  
The cells were washed in PBS and then lysed in cell lysis buffer comprising 50 mM Tris-
HCl (pH 8.0), 150 mM NaCl, 5 mM EDTA, 1% NP-40 (Igepal CA-630), 0.5% Na-
deoxycholate, 2 mM Na3VO4 (Wako Pure Chemicals Industries Ltd., Japan), and 
complete protease inhibitor cocktail (Roche, CH, Switzerland). The resulting cell lysates 
were centrifuged for 20 min at 15,000 rpm in a Kubota 3500 centrifuge with RA-2024 
rotor (Kubota Corporation, Tokyo, Japan) at 4°C, and the protein concentrations in the 
supernatants were determined using a BCA protein assay kit (Pierce, IL, USA). Equal 
amounts of proteins were loaded onto SDS-PAGE gels (8% or 15%), followed by 
electro-transfer onto polyvinylidene diﬂuoride membranes (Millipore, NJ, USA). The 
membranes were blocked in 1 × TBST (0.1% Tween-20, 20 mM Tris-Cl (pH 8.0), and 
150 mM NaCl) containing 5% skimmed milk and then incubated with the appropriate 
primary antibodies overnight at 4°C. Unbound antibodies were removed by washing 
with 1 × TBST and then the membranes were incubated with horseradish peroxidase-
conjugated secondary antibodies for 1 hour at room temperature. Finally, 
immunoreactive proteins were detected using ECL-plus or ECL-Prime reagent (GE 
Healthcare, Uppsala, Sweden). 
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3.5 Reverse transcription-real time PCR (RT-rtPCR)  
Total RNAs were extracted using a RNeasy mini kit (Qiagen, Hilden, Germany) and 
then cDNAs were synthesized from 1 μg of total RNA using Superscript III reverse 
transcriptase (Invitrogen, Tokyo, Japan). Real time PCR (rtPCR) analyses were 
performed using GoTaq qPCR Master Mix (A6001; Promega), the DNA engine Opticon 
2 system (MJ Research, Tokyo, Japan), and specific primer pairs for p21, c-ABL and β-
actin. The expression levels of the target genes were normalized to those of 
endogenous β-actin. The sequences of primers were as follows: 
 
Table 2.2 RT-PCR primers list  
Gene Primer sequence 5’ – 3’ (Forward) Primer sequence 5’ – 3’ (Reverse) 
p21 5′-ACTGTGATGCGCTAATGGC-3′ 5′-ATGGTCTTCCTCTGCTGTCC-3′ 
c-ABL 5′-CCCAACCTTTTCGTTGCACTGT-3′ 5′-CGGCTCTCGGAGGAGACGTAGA-3′ 
β-actin 5′-AGGAGAAGCTGTGCTATGTCG-3′ 5′- ACCAGACAGCACTGTGTTGG-3′ 
 
3.6 Cell cycle analyses  
For synchronization, the cells were treated with 2 mM thymidine for 24 h, and then 
grown in fresh media containing 2 mM thymidine or 100 ng/ml nocodazole for an 
additional 24 h. The synchronous or asynchronous cells were treated with 0.08 μg/ml 
ADR and 10 μM STI571 for different time periods. The cells were then trypsinized, 
washed, collected, and fixed with 70% ethanol. Fixed cells were centrifuged, treated 
with 10 μg/ml propidium iodide (BioLegend, San Diego, CA, USA), 100 μg/ml RNase 
(Qiagen) and 0.05% Triton X-100, and then analysed with an Accuri C6 Flow Cytometer 
(BD Biosciences, Tokyo, Japan). After flow cytometry analysis, the fractions of cells in 
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each phase (G1, S, and G2) of the cell cycle were calculated using FlowJo software 
Version 7.6.5 (Tree Star, Inc., Ashland, OR, USA). 
 
3.7 Senescence assay  
Cellular senescence was measured as senescence-associated-β-galactosidase (SA-β-
gal) activity, which was detected with a senescence detection kit (# k320-250, 
BioVision, Mountain View, CA, USA). Cells were stained for 24 h at 37°C and observed 
under a BZ-9000 microscope (Keyence, Osaka, Japan). The percentage of SA-β-gal-
positive cells was calculated from the numbers of blue-stained (SA-β-gal-positive) cells 
and the total number of cells. At least ten independent fields were examined in each 
experiment.
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 4. RESULTS 
4.1. c-ABL is indispensable for the induction of p21 during DNA damage response  
The role of c-ABL in the regulation of p21 expression upon DNA damage insult was 
examined using U2OS osteosarcoma cells overexpressing a luciferase gene under the 
control of the p21 promoter (p21-Luc) and either a c-ABL WT expression plasmid or 
empty vector (MSCV) as a control. Under unstressed conditions (no DNA damage), the 
luciferase activity of cells overexpressing c-ABL WT was 1.7-fold higher than that of 
cells transfected with the empty vector; this increase was not affected by the treatment 
of the cells with the c-ABL kinase inhibitor STI571 (Fig. 4.1A). These results are 
consistent with previous reports (Jing et al., 2007; Nie et al., 2000). Unexpectedly, 
following treatment of cells with double stranded DNA damaging agent ADR, the activity 
of the p21 promoter in cells overexpressing c-ABL WT was 2-fold higher than that in the 
control cells, and this increase was completely inhibited when the cells were incubated 
with STI571 (Fig. 4.1B). RT-PCR (Fig. 4.1C) and immunoblot (Fig. 4.1D) analyses of 
p21 expression confirmed the results of the luciferase assays; treatment of cells with 
ADR increased the expression levels of the endogenous p21 transcript and protein by 
30-fold. This dramatic induction of p21 by ADR was almost completely abrogated by 
exposure of cells to STI571. A dose-response analysis revealed that, under unstressed 
conditions, the activity of the p21 promoter was not affected by concentrations of 
STI571 up to 15 μM (Fig. 4.1E), which excludes the possibility of toxic side effects of 
this agent. By contrast, the inhibition of p21 induction by STI571 in ADR-treated cells 
occurred in a concentration-dependent manner (Fig. 4.1F and Fig. 4.1G). Of note, 
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U2OS cells expressed wild type c-ABL and that STI571 treatment did not affect a 
protein level of c-ABL (data not shown). 
 
Figure 4.1. Inhibition of c-ABL kinase activity by STI571 severely compromises ADR-induced 
p21 expression. (A, B) U2OS cells were co-transfected with 1 µg of MSCV empty vector or a vector 
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expressing c-ABL WT, together with 100 ng of p21-Luc reporter plasmid and 10 ng of pRL-CMV internal 
reporter. The cells were incubated in the absence or presence of ADR (0.4 µg/ml) and/or STI571 (10 µM) 
as indicated. Protein lysates were prepared from the cells and the relative luciferase activity was 
measured. Data from a representative example of n = 3 independent experiments are shown. (C) The 
U2OS cells, which contains WT c-ABL, were treated with ADR (0.4 μg/ml) and/or STI571 (10 μM) for 48 
h. Total RNAs were isolated from the harvested cells and used as templates for reverse transcription. The 
synthesized cDNA was subjected to rtPCR analysis and the levels of p21 transcripts were measured. The 
expression levels in triplicate samples were normalized to those of endogenous β-actin, and then to the 
expression level of the untreated control. (D) The cells were treated as in (C), and then protein lysates 
were prepared and processed for immunoblot analyses; the images are representative of 3 independent 
experiments (left), the protein levels of p21 and p53 were quantified by ImageJ densitometry software 
(right) and are expressed as the mean ±SD, of 3 independent experiments, relative to untreated control 
after normalizing to tubulin. (E, F) U2OS cells were co-transfected with 100 ng of p21-Luc and 10 ng pRL-
CMV vectors, and then treated for 48 h with increasing concentrations of STI571 in the absence or 
presence of ADR (0.4 µg/ml). The results are presented as described for (A, B). (G) The cells were 
cultured in the absence or presence of ADR (0.4 µg/ml) and increasing concentrations of STI571 for 48 h. 
Protein lysates were then prepared and processed for immunoblot analyses; the representative images of 
3 independent experiments (left), the relative p21 and p53 protein levels normalized to tubulin (right). (H) 
The cells were treated with ADR (0.4 μg/ml) alone or ADR plus STI571 (10 μM) for the indicated time 
periods. Protein lysates were used in immunoblot analyses; the representative images of 3 independent 
experiments (left), the relative p21 and p53 protein level normalized to tubulin (right). Data are 
represented as the mean ± SD of n = 3 independent experiments. ∗ P < 0.05; ∗∗ P < 0.01; NS, not 
significant. 
 
The p21 gene is a major transcriptional target of p53 (el-Deiry et al., 1993). 
Expression levels of p53 protein were markedly up-regulated following ADR treatment 
of cells; however, unlike p21 expression, this induction was not entirely abrogated by 
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STI571 treatment (Fig. 4.1D and Fig. 4.1G). Therefore, the time course of the induction 
of these proteins after DNA damage was examined by immunoblotting. Whereas 
induction of p53 was detected at the 4 h time-point, induction of p21 was only evident 
24 h after treatment with ADR (Fig. 4.1H). The immunoblot analyses also confirmed that 
the induction of p21, but not p53, was entirely inhibited by STI571. The results indicate 
that the induction of p53 alone upon DNA damage is not sufficient for the late and 
STI571-sensitive induction of p21.  
 
Figure 4.2. Knock-down of c-ABL decreases p21 expression. U2OS cells were transfected with 
siRNA c-ABL (2), siRNA c-ABL (3), siRNA c-ABL (4), or a control siRNA (siRNA-NC), and incubated for 
24 h. ADR (0.4 µg/ml) was then added and the cells were cultured for a further 48 h. (A, B, C) RNAs were 
prepared and processed for RT-rtPCR analyses. The expression levels of p21 and c-ABL were 
normalized to those of β-actin, and then to the levels in the control cells. (A) PCR products were 
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separated by agarose gel electrophoresis. (B, C) Data are represented as the mean ± SD of n = 3 
independent experiments. ∗∗ P < 0.01. (D) Protein lysates were processed for immunoblot analyses.   
 
To examine whether the effects of STI571 described above were attributable to a 
specific effect on c-ABL, endogenous c-ABL was knocked down using three different c-
ABL-specific siRNAs (siRNA2, siRNA3, siRNA4) and cells were treated with ADR to 
induce DNA damage. As expected, siRNA2, siRNA3, and siRNA4 significantly 
decreased the levels of endogenous c-ABL mRNA by 86%, 92%, and 97%, respectively 
(Fig. 4.2A and Fig. 4.2B). The expression levels of p21 mRNA were also significantly 
lower in cells transfected with the c-ABL-specific siRNAs than those transfected with a 
non-specific control siRNA (Fig. 4.2A and Fig. 4.2C). The p21 protein levels were lower 
in the c-ABL-specific siRNA-transfected cells than the control cells, while those of p53 
were unaffected by knock-down of c-ABL (Fig. 4.2D). These results indicate that the 
kinase activity of c-ABL is essential for the induction of p21 upon DNA damage 
response. Since the induction of p53 itself was not affected like that of p21 by the 
absence of c-ABL, these results also suggest that p53 alone may not be sufficient to 
induce p21. 
 
4.2. Inhibition of c-ABL kinase activity by STI571 augments ADR-induced 
apoptosis 
Given the importance of c-ABL in the regulation of p53 dependent induction of p21, I 
examined the biological significance of this phenomenon in the regulation of cell fate 
decision in response to DNA damage. Our group previously determined that the 
majority of U2OS cells underwent senescence following treatment with a low (0.08 
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µg/ml) concentration of ADR, or apoptosis following treatment with a high (0.4 µg/ml) 
concentration of ADR (S.I., unpublished results). Treatment of U2OS cells with either 
concentration of ADR induced p21 mRNA and protein production, which were both 
inhibited by exposure of the cells to 10 μM STI571 (Fig. 4.3A and Fig. 4.3B). Both 
concentrations of ADR also induced p53 protein expression and its phosphorylation at 
Ser15, which were not as much sensitive as p21 to STI571 (Fig. 4.3B).  
U2OS cells treated with a high concentration of ADR (0.4 µg/ml) were then stained 
with propidium iodide and analysed by flow cytometry. In the absence of ADR, only 1% 
of the cells were in sub-G1 population; however, this number increased to 14% 
following ADR treatment (Fig. 4.3C and Fig. 4.3D). Co-incubation of cells with ADR and 
STI571 increased the sub-G1 proportion to 21%; this sub-G1 fraction corresponded to 
apoptotic cells, as evident from morphological observations (Fig. 4.4). This result 
suggests that c-ABL antagonizes cellular apoptosis by sustaining p53-dependent 
induction of p21, which was shown to be anti-apoptotic in many ways. This observation 
was opposite to pro-apoptotic function of c-ABL via activation of p63/p73 previously 
described (Agami et al., 1999; Costanzo et al., 2002; Gonfloni et al., 2009; Gong et al., 
1999; White and Prives, 1999). 
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Figure 4.3. Inhibition of c-ABL kinase activity by STI571 enhances ADR-induced apoptosis. U2OS 
cells were treated with varying concentrations of ADR (0, 0.08, or 0.4 μg/ml) and/or STI571 (10 μM) for 48 
h. (A) RT-rtPCR analysis of the levels of p21 mRNA. Data are represented as the mean ± SD of n = 3 
independent experiments. ∗∗ P < 0.01. (B) Immunoblot analyses of the indicated proteins; the images are 
representative of 3 independent experiments (left), the protein levels of p21, p53 and p-p53 ser15 were 
quantified by ImageJ densitometry software (right) and are expressed as the mean ±SD, of 3 independent 
experiments, relative to untreated control after normalizing to tubulin. (C, D) Flow cytometric analysis of 
the DNA content in control cells and cells exposed to a higher concentration of ADR (0.4 μg/ml), in which 
substantial fraction of U2OS cells undergo apoptosis, and/or STI571 (10 μM) for 48 h. Cells were stained 
with propidium iodide and then analysed using an Accuri C6 flow cytometer. (C) Representative flow 
cytometry histograms are shown; the numbers indicate the percentages of cells in the sub-G1 phase in 
the examples shown. (D) Percentages of cells in the sub-G1 phase obtained from the results in (C). The 
data are represented as the mean ± SD of n = 3 independent experiments. ∗ P < 0.05, ∗∗P  < 0.01.  
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Figure 4.4. Morphological characteristics of the apoptotic cells compared to the normal cells. 
U2OS cells were treated with a higher concentration of ADR (0.4 μg/ml) and/or STI571 (10 μM) for 48 h. 
The photographs were taken at a bright field with 40-fold magnification (scale bar, 100 µm). 
   
4.3. Inhibition of c-ABL activity by STI571 relieves ADR-induced G2 cell cycle 
arrest 
p21 is a potent cyclin-dependent kinase inhibitor that plays a crucial role in cell cycle 
control. In addition, c-ABL is known to cause cell cycle arrest (Sawyers et al., 1994; 
Wagner et al., 2008; Wang et al., 2011). Therefore, the role of c-ABL in the control of 
cell cycle progression was examined. In addition to U2OS cells, HeLa and A549 cells 
were also analysed by flow cytometry (Fig. 4.5A–C). In all cell lines, approximately 16–
20% of control (untreated) cells were in the G2 phase. Treatment of cells with a low 
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(0.08 µg/ml) concentration of ADR increased this number to 79–94%, indicating ADR-
induced G2-arrest. Interestingly, co-treatment of cells with both ADR and STI571 
reduced the percentage of cells in the G2 phase (54–84%) and increased the number of 
cells in the G1 (17–30%) and S (13–24%) phases. These data indicate that STI571 
relieves ADR-induced G2-arrest, most likely as a consequence of STI571 interfering 
with p53 dependent induction of p21.  
In the experiment described above (Fig. 4.5), the cells were cultured under an 
asynchronous condition. Cell synchronization experiments, in which U2OS cells were 
untreated (Fig. 4.6A–C), blocked at the G1 phase by double thymidine treatment (Fig. 
4.6D–F), or blocked at the G2 phase by thymidine-nocodazole treatment (Fig. 4.6G–I), 
were also performed. Cells were blocked at time 0 and then released from the block and 
treated with ADR, STI571, or both for up to 48 h. Following release from the G1 block, 
the number of cells in the S-phase rapidly increased from 10% to 23% when no drug 
was added to the culture medium; however, this increase was not observed when the 
cells were treated with ADR (Fig. 4.6E). This result indicates that the S-phase 
checkpoint was functioning properly in the cells. When the cells were released from the 
G1 block and treated with a combination of ADR and STI571, the number of S-phase 
cells was recovered to 18%. This inhibition of S-phase entry by ADR and its relief by 
STI571 were also observed for cells released from the G2 block (Fig. 4.6H). Thus, the 
S-phase checkpoint was prolonged or postponed when c-ABL kinase activity was 
inhibited. 
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Figure 4.5. Inhibition of c-ABL kinase activity by STI571 relieves ADR-induced G2 cell cycle arrest. 
U2OS (A), HeLa (B), and A549 cells (C) were treated with a lower concentration of ADR (0.08 μg/ml), in 
which substantial fraction of U2OS cells undergo senescence, and/or STI571 (10 μM) for the indicated 
time periods. The cells were stained with propidium iodide and the DNA content was measured by flow 
cytometry. The percentages of cells in each phase (G1, S, and G2) of the cell cycle are shown.  
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Figure 4.6. In the presence of ADR, inhibition of c-ABL kinase activity prolongs S-phase 
checkpoint and relieves G2-arrest. U2OS cells were treated with DMSO as a control (A–C) or 2 mM 
thymidine (D–I) for 24 h, and then incubated in fresh medium containing DMSO (A–C), 2 mM thymidine  
(D–F), or 100 ng/ml nocodazole (G–I) for an additional 24 h. The cells were incubated with fresh medium 
containing a lower concentration of ADR (0.08 μg/ml), in which substantial fraction of U2OS cells undergo 
senescence, and/or STI571 (10 μM) for the indicated time periods. The cells were stained with propidium 
iodide and the DNA content was measured by flow cytometry. The percentages of cells in each phase 
(G1, S, and G2) of the cell cycle are shown. 
 
4.4. c-ABL tyrosine kinase augments ADR-induced senescence 
 The p53-p21 pathway is well-known pathway for the induction of senescence 
(Brown et al., 1997; McConnell et al., 1998; Stein et al., 1999; Tahara et al., 1995); 
therefore, the possible role of c-ABL in cellular senescence was investigated. U2OS 
cells were treated with a low (0.08 µg/ml) concentration of ADR and/or STI571 (10 μM), 
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and then processed for SA-β-gal staining, which is a marker of senescence (Dimri et al., 
1995; Elmore et al., 2002). The percentage of SA-β-gal positive cells reached 77% after 
ADR treatment, while only 19% of STI571-treated cells were SA-β-gal positive (Fig. 
4.7A and Fig. 4.7B). Here, p21 expression was sustained in the senescent cells, 
whereas that was reduced in the cells inhibited for senescence by STI571 (Fig. 4.7C). 
Similar results were obtained when HeLa or A549 cells were treated with ADR and/or 
STI571 (Fig. 4.8). Knock-down of c-ABL using a specific siRNA also led to a dramatic 
reduction of SA-β-gal positive cells from 68% to 33% (Fig. 4.7D and Fig. 4.7E). These 
results indicate that c-ABL kinase is positively involved in the development of 
senescence through induction of p21 in cells that are arrested at the G2 phase after 
ADR-induced DNA damage. 
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Figure 4.7. c-ABL kinase is required for ADR-induced cellular senescence. (A, B, C) U2OS cells 
were treated without (control) or with a lower concentration of ADR (0.08 μg/ml) and/or STI571 (10 μM) 
for 96 h. (D, E) The cells were transfected with c-ABL-specific siRNA2 or a non-specific control siRNA 
(NC), incubated for 24 h, and then treated with ADR (0.08 μg/ml) for a further 96 h. (A, B, D, E ) Treated 
cells were stained for SA-β-gal activity. (C) The protein lysates were prepared and processed for 
immunoblot analyses.  (A, D) The photographs were taken in a bright field with 200-fold magnification 
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(scale bar, 100 µm). (B, E) The numbers of SA-β-gal positive cells were calculated as a percentage of the 
total number of cells. Three independent experiments were performed and the cells present in at least ten 
independent fields were counted in each experiment. Data are represented as the mean ± SD. ∗∗P < 
0.0001.  
 
Figure 4.8. Inhibition of c-ABL kinase activity by STI571 reduces the percentages of SA-β-gal 
positive cells. HeLa (A) and A549 (B) cells were treated without (Control) or with a lower concentration 
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of ADR (0.08 μg/ml) and/or STI571 (10 μM) for 96 h, and then (A, B) stained for SA-β-gal activity. The 
photographs were taken at a bright field with 200-fold magnification (scale bar, 100 µm). The numbers of 
SA-β-gal positive cells were calculated as a percentage of the total number of cells. Three independent 
experiments were performed and the cells present in at least ten independent fields were counted in each 
experiment. Data are represented as the mean ± SD. ∗∗P < 0.0001 
.
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 5. DISCUSSION AND FUTURE PERSPECTIVES 
c-ABL is a stress-induced protein, which is activated in response to DNA damage and 
shown to plays a vital role in proapoptotic function largely independent on p53 
(Kharbanda et al., 1998b; Shaul and Ben-Yehoyada, 2005). In this study we 
demonstrated for the first time that c-ABL also plays a pivotal role in cell fate 
determination in response to DNA damage by modulating p53 dependent induction of 
p21.  
When DNA damage is irreparable, cells will undergo apoptosis or cellular 
senescence. Although the mechanism determining the choice between apoptosis and 
senescence is currently unclear, the data presented here indicate that the exposure of 
cells to a relatively low dose of DNA damaging agent ADR induces cell cycle arrest and 
senescence, and relatively high dose of ADR induces apoptosis in several human 
cancer cell lines. In DNA damage responses, the c-ABL was shown to participate in cell 
cycle arrest and apoptosis through activation of p53 (Sawyers et al., 1994; Wagner et 
al., 2008; Wang et al., 2011) and p63/p73 (Agami et al., 1999; Gonfloni et al., 2009; 
Gong et al., 1999; White and Prives, 1999), respectively. In addition, this study clearly 
demonstrated that c-ABL tyrosine kinase modulates p53-dependent cell fate decision in 
response to DNA damage by regulating p53-dependent induction of p21. I clearly 
showed that c-ABL tyrosine kinase was indispensable for p53-dependent induction of 
p21, known to induce cell cycle arrest and senescence, while inhibiting p53-dependent 
apoptosis (Bissonnette and Hunting, 1998; Bunz et al., 1999; Gartel and Tyner, 2002; 
Han et al., 2002; Janicke et al., 2007; Suzuki et al., 2013; Xu and El-Deiry, 2000). Under 
light DNA damage, cells were blocked at the G2 phase of the cell cycle and most cells 
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underwent senescence eventually. When c-ABL kinase was inhibited by STI571, the 
cells were no longer capable of expressing p21 despite the accumulation of p53. This 
reduction of p21 is speculated to abrogate G2-arrest, and cellular senescence, which is 
largely dependent on p21 function. Under severe DNA damage, cells underwent 
apoptosis. When c-ABL kinase was inhibited by STI571, the cells undergoing apoptosis 
augmented. This observation is opposite from pro-apoptotic function of c-ABL via 
activation of p63/p73 described earlier (Agami et al., 1999; Costanzo et al., 2002; 
Gonfloni et al., 2009; Gong et al., 1999; White and Prives, 1999). I reasoned that 
abrogation of p53-dependent p21 induction led to elimination of inhibitory effects of 
apoptosis by p21. Of note, many of the earlier work utilized exogenous overexpression 
of p53 family genes, whereas I entirely depended on cells with endogenous p53 family 
gene expression to draw the conclusion. 
The p53-p21 pathway is one of the major tumour-suppression pathways implicated 
in cellular senescence (Chang et al., 1999; Hsu et al., 2012). This stress-induced 
senescence is different from replicative senescence, which is induced by telomere 
attrition (d'Adda di Fagagna, 2008). Recently, mouse c-Abl has been reported to 
negatively regulate replicative senescence; c-Abl-/- mouse embryonic fibroblasts tend to 
express elevated levels of p16INK4a, p53 and p21, all of which appear to contribute to the 
reduced proliferative capacity and premature senescence of cells (Zhang et al., 2013). 
Conversely, I observed that under unstressed conditions the inhibition of c-ABL kinase 
led to only a subtle increase in p21 levels resulting in a slightly reduced cell proliferation 
rate without having the effect on cellular senescence. By contrast, during the DNA 
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damage response, the inhibition of c-ABL kinase or knock-down of c-ABL severely 
impaired p21 induction, causing cells to escape from ADR-induced senescence.  
With regard to the relationship among c-ABL, p53, and p21, three important pieces 
of evidence have been reported previously. First, the p21 gene is a major transcriptional 
target of p53 (el-Deiry et al., 1993). Second, c-ABL kinase affects the activation status 
of p53 (Wang et al., 2011), and third, c-ABL can induce p21 gene transcription in a p53-
dependent but kinase-independent manner (Jing et al., 2007; Yuan et al., 1996b). Jing 
et al., 2007 and Yuan et al., 1996b, had not considered DNA damage condition and 
carried out their experiments under unstressed condition, in the absence of DNA 
damage. Consistent with their findings I also observed that under unstressed condition, 
c-ABL induces p53-dependent p21 gene transcription in a kinase-independent manner. 
In DNA damage response, however, I found that kinase activity of c-ABL is essential for 
p53-dependent p21 induction. In this study, I observed that ADR-induced senescence is 
not only associated with the induction of p21 induction, but is also mediated by c-ABL. 
Inhibition of c-ABL kinase activity by STI571 or knock-down of c-ABL reduced the DNA 
damage-induced p21 induction to its basal level but had only marginal effects on p53 
expression. Therefore, the kinase activity of c-ABL appears to be indispensable for p21 
induction following DNA damage.  
Another signaling pathway critical for activating p53 is acetylation. p53 acetylation 
induced by DNA damage was reported to increase the binding preferences of CBP 
towards the p21 promoter. Consequently, acetylated histones H3 and H4 are tightly 
bound to p21 promoter for its induction in the U2OS cells (Barlev et al., 2001). This 
implies that the acetylation of p53, as well as histone H3/H4 is also a critical 
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determinant for p53-dependent p21 induction. Furthermore, c-ABL kinase has been 
shown to have a role in p73 acetylation in response to ADR-induced DNA damage 
(Costanzo et al., 2002). Thus, I speculate that c-ABL may also play a crucial role for 
acetylation of p53, as well as histone H3/H4. In preliminary experiments I found that 
TSA (HDACs inhibitor) treatment enhanced adriamycin-induced p21 expression, which 
was blocked when cells were treated with ABL kinase inhibitor, implying c-ABL kinase is 
essential for acetylation dependent activation of p53. Moreover, I also found that c-ABL 
kinase enhanced p53 acetylation, which was diminished when c-ABL kinase activity 
was inhibited. Despite this dependence on c-ABL kinase activity, I could not find any 
putative ABL kinase phosphorylation site in HDACs through in silico approaches. 
However, I found two putative ABL kinase phosphorylation sites, Y335 and Y339, in the 
proline rich region of MTA2, which is a component of nucleosome remodelling and 
histone deacetylation (NuRD) complexes and is involved in both nucleosome 
remodelling and histone/non-histone proteins deacetylation in association with HDACs. 
It has been reported that the overexpression of MTA2 significantly diminished p53 
acetylation, leading to a great diminution of p53-dependent p21 gene expression; while 
TSA treatment substantially abrogated deacetylation of p53 by MTA2 (Luo et al, 2000). 
Thus, I will attempt to decipher the comprehensive molecular mechanism underlying the 
regulation of p53-dependent p21 induction taking these facts into consideration (Figure 
5.1).  
 
Figure 5.1 c-ABL may also regulate p53-dependent p21 induction by abrogating NuRD complex 
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It is generally accepted that p21 regulates cell cycle progression at either the G1 or 
G2 checkpoint by inhibiting the activity of cyclin-CDK2 or cyclin-CDC2 (also known as 
CDK1) complexes, respectively (Cmielova and Rezacova, 2011). Likewise, c-ABL 
kinase can regulate both G1 and G2 checkpoint control via the induction of p21 (Goga 
et al., 1995; Wagner et al., 2008; Wang et al., 2011; Yuan et al., 1996b). In the case of 
the DNA damage response, a number of pieces of evidence suggest that a role of c-
ABL and p21 in the regulation of G2 specific checkpoint rather than G1. First, c-ABL is 
activated after DNA damage upon degradation of RB at the late G1/early S-phase, 
which is later than G1checkpoint (Shaul, 2000; Wang, 2000). Second, p21 is 
synthesized in the G2 phase and is essential for maintaining G2-arrest (Bunz et al., 
1998; Dulic et al., 1998); this p21 is involved in the inactivation of CDC2 (Smits et al., 
2000). Third, c-ABL can directly inactivate CDC2 (Lin et al., 2004). Through these 
mechanisms, c-ABL kinase seems to inhibit the cyclin B1-CDC2 complex and promote 
a G2 block. In fact, this study found that, in the presence of a relatively low dose of 
ADR, the inhibition of c-ABL kinase activity impaired the G2-arrest, allowing substantial 
numbers of cells to escape from the G2 block and enter into the G1 and S phases. 
Therefore, c-ABL kinase is required for ADR-induced G2 cell cycle arrest and is 
indispensable for the induction of p21. Considering that p53 and p21 are essential for 
maintaining G2 checkpoint during the DNA damage response (Bunz et al., 1998), it 
seems likely that c-ABL kinase induces G2-arrest by activation of the p53-p21 pathway.  
This study revealed that cancer cells escape from ADR-induced G2-arrest and 
senescence when c-ABL kinase activity is inhibited by STI571. This observation is 
intriguing in light of the fact that most cancer cells are defective for G1 checkpoint 
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control. It is possible that, when such cells are treated with STI571 and low dose of the 
DNA damaging agents simultaneously, they lose the ability to undergo G2- (and G1-) 
arrest and senescence, and so become more resistant to chemotherapeutic agents. In 
this condition the cells continue to proliferate due to abrogation of G2 arrest and will 
accumulate damaged DNA resulting in eventual cell death. Indeed, G2 checkpoint 
abrogator in combination with DNA damaging agent is postulated as ideal condition for 
cancer treatment (Kawabe, 2004).  Because normal cells with proper G1-check point 
will enable damaged DNA to be repaired, and cancer cells with no check point available 
will be killed eventually.  Despite this postulation, cells administered with a low dose 
ADR plus STI571 continued to grow for at least five days, whereas cells administered 
with a low dose ADR only clearly senesced, which indicates G2 check point abrogator, 
STI571 did not work to kill cells in combination with DNA damaging agent, a low dose 
ADR.  The present study clearly demonstrated that the postulation can only be applied 
under a high dose ADR treatment along with STI571. Since ADR is used in the 
treatment of numerous malignancies including breast, ovarian, and endometrial cancers 
as well as lymphomas and acute leukemia, alone or in combination with STI571 
(Fruehauf et al., 2007; Soleimani et al., 2011); findings of the present study suggest that 
the combined use of ABL kinase inhibitors and DNA damaging agent in chemotherapy 
should be carefully designed so as to augment the cytotoxic effect of chemotherapeutic 
drugs. I recommend a dose of DNA damaging drug should exceed the threshold of 
apoptosis induction, in which condition STI571 will augment the cytotoxic effect of the 
drug and not in the range of senescence induction, in which condition STI571 will 
interfere with the cytotoxic effect of the drug (Figure 5.2). The combined use of the c-
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ABL kinase inhibitor STI571 (Glivec) and DNA damaging drug, indeed, has a synergistic 
effect on apoptosis of chronic myelogenous leukemia cells bearing wild-type p53 
(Fruehauf et al., 2007; Goldberg et al., 2004). 
 
Figure 5.2 Clinical impact of the combined therapy of Glivec and DNA damaging drugs 
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 6. CONCLUSION 
c-ABL tyrosine kinase proved to be prerequisite for the p21 induction by p53 in 
response to DNA damage.  Thus, low concentration of ADR leading to cell cycle arrest 
and senescence, which is largely dependent on p53-dependent induction of p21, was 
abrogated by simultaneous presence of STI571; and high concentration of ADR leading 
to apoptosis, which is inhibited by p53 dependent induction of p21, was augmented by 
simultaneous presence of STI571.  These findings suggest that the combined use of 
ABL kinase inhibitor and DNA damaging agent in chemotherapy should be carefully 
designed so as to augment the cytotoxic effect of chemotherapeutic drugs.
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